Skip to Content

Press Releases

Press Releases

Mar 14 2016
Intec Pharma Ltd. Announces Availability of Its Annual Report on Form 20-F Through Its Website
JERUSALEM, ISRAEL--(Marketwired - Mar 14, 2016) - Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: INTP), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, announced today that its annual report on Form 20-F, containing
Mar 14 2016
Intec Pharma Ltd.: Notice of Special General Meeting of Shareholders
JERUSALEM, ISRAEL--(Marketwired - Mar 14, 2016) - Notice is hereby given that the special general meeting of shareholders of Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: INTP) (the " Company "), will be held at the offices of Gross, Kleinhendler, Hodak, Halevy, Greenberg & Co., One Azrieli Center, Round
Mar 10 2016
Intec Pharma Completed a Phase I Clinical Trial With Its Third Pipeline Product
JERUSALEM, ISRAEL--(Marketwired - Mar 10, 2016) -  Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: INTP), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, today announced that it has completed a Phase I clinical trial with
Jan 05 2016
Intec Pharma to Present at Biotech Showcase 2016
JERUSALEM, ISRAEL--(Marketwired - Jan 5, 2016) - Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: INTP), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, today announced that its Chief Executive Officer, Zeev Weiss, will
Dec 16 2015
Intec Pharma Further Expands Intellectual Property With a New Patent for the Accordion Pill Zaleplon in Europe
JERUSALEM, ISRAEL--(Marketwired - Dec 16, 2015) - Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: INTP), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, today announced that the Company has been informed by the European
Dec 14 2015
Intec Pharma Receives an IRB Approval to Initiate Phase III Clinical Trial of AP - CDLD for the Treatment of Parkinson's Disease
JERUSALEM, ISRAEL--(Marketwired - Dec 14, 2015) - Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: INTP), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, today announced that it has received a US centralized institutional
Dec 08 2015
Intec Pharma Enters Phase I Clinical Trial With Its Third Pipeline Product
JERUSALEM, ISRAEL--(Marketwired - Dec 8, 2015) - Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: INTP), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, today announced that it is entering a Phase I clinical trial with its
Nov 05 2015
Intec Pharma Reports Results for the Third Quarter of 2015
JERUSALEM, ISRAEL--(Marketwired - Nov 5, 2015) -   Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: INTP) ("Intec Pharma" or the "Company"), an Israeli clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, today announced its
Oct 22 2015
Intec Pharma Expands Intellectual Property With a New Patent for the Accordion Pill in Europe
JERUSALEM, ISRAEL--(Marketwired - Oct 22, 2015) -  Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: INTC), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, today announced that the Company has been informed by the European
Oct 12 2015
Intec Pharma Announces Topline Results of a Food Effect, Pharmacokinetic Study of AP-CDLD 50/500mg for the Treatment of Parkinson's Disease Symptoms
JERUSALEM, ISRAEL--(Marketwired - Oct 12, 2015) -  Intec Pharma Ltd . (NASDAQ: NTEC) (TASE: INTC), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, today announced results of the food effect study of the Phase 3
Displaying 71 - 80 of 81